Showing 5 of total 5 results (show query)
drizopoulos
JMbayes2:Extended Joint Models for Longitudinal and Time-to-Event Data
Fit joint models for longitudinal and time-to-event data under the Bayesian approach. Multiple longitudinal outcomes of mixed type (continuous/categorical) and multiple event times (competing risks and multi-state processes) are accommodated. Rizopoulos (2012, ISBN:9781439872864).
Maintained by Dimitris Rizopoulos. Last updated 25 days ago.
competing-riskslongitudinal-analysismixed-modelsmulti-statepersonalized-medicineprecision-medicineprediction-modelsurvival-modelsopenblascppopenmp
84 stars 8.27 score 264 scripts 2 dependents
jaredhuling
personalized:Estimation and Validation Methods for Subgroup Identification and Personalized Medicine
Provides functions for fitting and validation of models for subgroup identification and personalized medicine / precision medicine under the general subgroup identification framework of Chen et al. (2017) <doi:10.1111/biom.12676>. This package is intended for use for both randomized controlled trials and observational studies and is described in detail in Huling and Yu (2021) <doi:10.18637/jss.v098.i05>.
Maintained by Jared Huling. Last updated 3 years ago.
causal-inferenceheterogeneity-of-treatment-effectindividualized-treatment-rulespersonalized-medicineprecision-medicinesubgroup-identificationtreatment-effectstreatment-scoring
32 stars 7.38 score 125 scripts 1 dependents
nt-williams
lmtp:Non-Parametric Causal Effects of Feasible Interventions Based on Modified Treatment Policies
Non-parametric estimators for casual effects based on longitudinal modified treatment policies as described in Diaz, Williams, Hoffman, and Schenck <doi:10.1080/01621459.2021.1955691>, traditional point treatment, and traditional longitudinal effects. Continuous, binary, categorical treatments, and multivariate treatments are allowed as well are censored outcomes. The treatment mechanism is estimated via a density ratio classification procedure irrespective of treatment variable type. For both continuous and binary outcomes, additive treatment effects can be calculated and relative risks and odds ratios may be calculated for binary outcomes. Supports survival outcomes with competing risks (Diaz, Hoffman, and Hejazi; <doi:10.1007/s10985-023-09606-7>).
Maintained by Nicholas Williams. Last updated 23 days ago.
causal-inferencecensored-datalongitudinal-datamachine-learningmodified-treatment-policynonparametric-statisticsprecision-medicinerobust-statisticsstatisticsstochastic-interventionssurvival-analysistargeted-learning
64 stars 6.37 score 91 scripts
levenc
posologyr:Individual Dose Optimization using Population Pharmacokinetics
Personalize drug regimens using individual pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) profiles. By combining therapeutic drug monitoring (TDM) data with a population model, 'posologyr' offers accurate posterior estimates and helps compute optimal individualized dosing regimens. The empirical Bayes estimates are computed following the method described by Kang et al. (2012) <doi:10.4196/kjpp.2012.16.2.97>.
Maintained by Cyril Leven. Last updated 20 days ago.
bayesianmodel-informed-precision-dosingpharmacokineticsprecision-medicinetherapeutic-drug-monitoring
12 stars 4.68 score 9 scripts
smartdata-analysis-and-statistics
precmed:Precision Medicine
A doubly robust precision medicine approach to fit, cross-validate and visualize prediction models for the conditional average treatment effect (CATE). It implements doubly robust estimation and semiparametric modeling approach of treatment-covariate interactions as proposed by Yadlowsky et al. (2020) <doi:10.1080/01621459.2020.1772080>.
Maintained by Thomas Debray. Last updated 6 months ago.
4 stars 4.20 score 4 scripts